Home › Forums › Main Forum › Media & News › Research and Trials › Switzerland article

Viewing 3 posts - 1 through 3 (of 3 total)
  • Author
    Posts
  • 25 August 2018 at 12:04 am #28497
    Avatar photoHazel
    • Guardian Angel
    • ★★★★★
    @hazel

    This is interesting, a journal article about DAA access in Switzerland and how they still need the generic importation mechanism, the tools they have still don’t cover everyone.
    We are similar here in NZ, about to get Mavyret for everyone but it leaves a treatment gap for those with more advanced cirrhosis.
    This article says, the worlds biggest ‘buyers club’ is, of course, FixhepC. :+1: :+1: #flower
    https://smw.ch/en/article/doi/smw.2018.14649/

    Genotype 3 30 years, 2x treatment interferon/ribavirin non responder. Cirrhosis 17 years. Fibroscan, decompensating, 40 down to 22 by 29/3/16- now down to 6.5, normal, no cirrhosis. Started Buyers Club Sof/Dac 14 Nov 15. SVR 12 29/0716

    25 August 2018 at 7:21 am #28501
    dope-on-a-rope.jpgDr James
    • Guardian Angel
    • ★★★★★
    @fixhepc

    Hi Hazel,

    Thanks for sharing.

    YMMV

    26 August 2018 at 3:00 am #28503
    Avatar photocoral
    • Guardian Angel
    • ★★★★★
    @coral

    Thanks Hazel. An interesting article that is trying to call it as it is and bring buyer’s clubs into the mix as a mainstream option. It really highlights those extraordinary price differences despite some negotiating for lower cost DAAs.

  • Author
    Posts
Viewing 3 posts - 1 through 3 (of 3 total)
  • You must be logged in to reply to this topic.